Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1513/AnnalsATS.202005-566FR http://scihub22266oqcxt.onion/10.1513/AnnalsATS.202005-566FR 32692580!7640626!32692580     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ann+Am+Thorac+Soc 2020 ; 17 (10): 1186-1194 Nephropedia Template TP {{tp|p=32692580|t=2020. Repurposing Existing Drugs for the Treatment of COVID-19 |pdf=|usr=}}{{32692580}} gab.com Text Repurposing Existing Drugs for the Treatment of COVID-19 JO: Ann Am Thorac Soc http://www.kidney.de/pget.php?&tw=1&pmid=32692580 #FOAvip The rapid global spread and significant mortality associated with the coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection has spurred an urgent race to find effective treatments. Repurposing existing drugs is a particularly attractive approach as pharmacokinetic and safety data already exist; thus, development can leapfrog straight to clinical trials of efficacy, generating results far more quickly than de novo drug development. This review summarizes the state of play for the principle drugs identified as candidates to be repurposed for treating COVID-19 grouped by broad mechanism of action: antiviral, immune enhancing, and antiinflammatory or immunomodulatory. Patient selection, particularly with regard to disease stage, is likely to be key. To date, only dexamethasone and remdesivir have been shown to be effective, but several other promising candidates are in trials. Twit Text FOAVip Repurposing Existing Drugs for the Treatment of COVID-19 ????Ann Am Thorac Soc http://www.kidney.de/pget.php?&tw=1&pmid=32692580 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32692580 #FOAvip English Wikipedia <ref>{{Cite pmid|32692580}}</ref> Repurposing Existing Drugs for the Treatment of COVID-19 #MMPMID32692580 Farne H; Kumar K; Ritchie AI; Finney LJ; Johnston SL; Singanayagam A Ann Am Thorac Soc 2020[Oct]; 17 (10): 1186-1194 PMID32692580show ga The rapid global spread and significant mortality associated with the coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection has spurred an urgent race to find effective treatments. Repurposing existing drugs is a particularly attractive approach as pharmacokinetic and safety data already exist; thus, development can leapfrog straight to clinical trials of efficacy, generating results far more quickly than de novo drug development. This review summarizes the state of play for the principle drugs identified as candidates to be repurposed for treating COVID-19 grouped by broad mechanism of action: antiviral, immune enhancing, and antiinflammatory or immunomodulatory. Patient selection, particularly with regard to disease stage, is likely to be key. To date, only dexamethasone and remdesivir have been shown to be effective, but several other promising candidates are in trials. |*Coronavirus Infections/drug therapy/epidemiology[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/drug therapy/epidemiology[MESH] |Anti-Inflammatory Agents/*pharmacology[MESH] |Antiviral Agents/*pharmacology[MESH] |Betacoronavirus/*drug effects[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Drug Discovery/methods[MESH] |Drug Repositioning/methods[MESH] |Humans[MESH] |Immunologic Factors/*pharmacology[MESH] |Patient Selection[MESH]Repurposing Existing Drugs for the Treatment of COVID-19 (epmc).pdf DeepDyve Pubget Overpricing